A key mechanism of Hsp90 inhibitors for cancer therapy is to regulate inflammatory responses via the regulation of secretory pathways, integrins, and toll-like receptor (TLR) signaling (Tsan and Gao, 2009). Here, HSP90AA1 is linked to cancer.